Pyxis Oncology
PYXS
78 hedge funds and large institutions have $40.5M invested in Pyxis Oncology in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 35 reducing their positions, and 14 closing their positions.
2,800% more call options, than puts
Call options by funds: $290K | Put options by funds: $10K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1% less funds holding
Funds holding: 79 → 78 (-1)
3.17% less ownership
Funds ownership: 48.5% → 45.33% (-3.2%)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
48% less capital inflows, than outflows
Capital inflows: $2.54M | Capital outflows: $4.93M
66% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HealthInvest Partners
Stockholm,
Sweden
|
+$740K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$695K |
| 3 |
Laurion Capital Management
New York
|
+$303K |
| 4 |
Renaissance Technologies
New York
|
+$242K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$217K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$861K |
| 2 |
Jane Street
New York
|
-$726K |
| 3 |
Millennium Management
New York
|
-$521K |
| 4 |
ExodusPoint Capital Management
New York
|
-$365K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$275K |
PYXS Hedge Fund Activity: Q1 2026 in Review
78 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2026, worth a combined $40.5M — up 17% from $34.7M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PYXS and 11 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 12 added.
The largest buyer was HealthInvest Partners, adding an estimated $740K. The largest seller was Bank of America, cutting an estimated $861K.
- 78 institutional investors held Pyxis Oncology (PYXS) as of Q1 2026, down from 79 in Q4 2025.
- Funds reported $40.5M of Pyxis Oncology stock for Q1 2026, up 17% quarter-over-quarter.
- 11 funds opened new Pyxis Oncology positions in Q1 2026 and 14 closed out, a net change of -3 holders.
- The largest Pyxis Oncology buyer in Q1 2026 was HealthInvest Partners, an estimated $740K added.
- The largest Pyxis Oncology seller in Q1 2026 was Bank of America, an estimated $861K sold.
Based on aggregated 13F filings for Q1 2026.